C8 Antibody (Monoclonal), Biotinylated

A biotin conjugated murine monoclonal antibody to an epitope on C8 protein.


Product Specifications

Citations 0
Clonality

Monoclonal

Immnogen
Applications See citations and technical data sheet for application info.
Concentration 0.2 mg/mL
Conjugate Biotin
Cross Reactivity

Human

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number A708
Catalog Number (CE) N/A
Size 250 µL
Price (USD) $365.00
Price (EURO) 330,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A biotin conjugated murine monoclonal antibody to an epitope on C8 protein.

Size 250 µL
Concentration

0.2 mg/mL

Applications See citations and technical data sheet for application info.
Form Liquid. Phosphate Buffered Saline (pH 7.0 ± 0.2), 1% Bovine Serum Albumin, with ≤ 0.1% Sodium Azide.
Clonality Monoclonal
Immunogen Purified human protein.
Conjugate Biotin
Cross Reactivity Human
Isotype IgG2ak
Purity ≥ 95% by SDS PAGE
Source

Mouse

Specificity This monoclonal Antibody was raised against purified human C8. It is specific for an Antigen expressed on native C8 as well as on C8 in the MAC. It will not inhibit the lysis of EA and will detect membrane bound MAC.
Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

Complement component C8 is a plasma glycoprotein with a molecular weight of 150 kD. C8 protein is present in human plasma at a concentration of approximately 70 µg/mL. Complement component C8 is unique to the Terminal Complement pathway. It is composed of three protein chains (α-65 kD, β-65 kD and γ-22 kD). Together with the other proteins of the Terminal pathway, C8 forms the Membrane Attack Complex or MAC. The Terminal Complement Complex (TCC) is the general term for both membrane bound C5b-9 (the MAC) and fluid phase SC5b-9. C5b-9 is formed through activation of the Terminal pathway via either the Classical or Alternative Complement pathways. Assessment of the TCC is an excellent marker for quantifying the extent of Terminal pathway activation in vivo or in vitro. TCC can be deposited on the su rface of transformed cells, biomaterials, and a variety of other surfaces.

Citations

Title Year Applications Sample Species Sample Sample Details